ArticleCancer research and treatment2026
BTG1 Mutation Correlates with Inferior Prognosis in Diffuse Large B-Cell Lymphoma.
Article in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeB-cell translocation gene 1 (BTG1) is a highly conserved gene and recurrently mutated in the MCD subtype of diffuse large B-cell lymphoma (DLBCL). The specific enrichment of BTG1 mutation (BTG1mut) raises a potential hypothesis that they may actively contribute to DLBCL. However, the biological characteristics and prognostic signifi cance ofBTG1 in DLBCL remain to be explored. Therefore, the objective of our study was to evaluate the value of BTG1 in DLBCL. MATERIALS AND
methodsThe available clinical information and corresponding mutation data of DLBCL were obtained from published articles. Tumor tissue samples of DLBCL patients diagnosed in Jiangsu Province Hospital (JSPH) from 2021 to 2023 were collected for next-generation sequencing, 195 samples were analyzed for gene expression levels using RNA sequencing, among them, 40 samples were analyzed by untargeted metabolomics.
resultsWe enrolled 2,379 DLBCL patients from fi ve published studies and 243 DLBCL patients from JSPH cohort. In external cohort, 11.0% (262/2,379) of patients were BTG1mut, compared with 25.1% (61/243) in the JSPH cohort. BTG1mut was associated with adverse clinical features and was prone to involve testis. Patients with BTG1mut exhibit inferior overall survival. Furthermore, pathway enrichment analysis of the untargeted metabolomics showed that several meaningful pathways have been found such as amino acid metabolism and lipid metabolism.
conclusionBTG1 mutation was promising prognostic predictor for DLBCL. The mechanism driving different survival outcomes may be attributed to the tumor metabolic reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.